{"nctId":"NCT03280264","briefTitle":"Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism","startDateStruct":{"date":"2017-08-30","type":"ACTUAL"},"conditions":["Parathyroid Carcinoma","Primary Hyperparathyroidism"],"count":18,"armGroups":[{"label":"KHK7580","type":"EXPERIMENTAL","interventionNames":["Drug: KHK7580"]}],"interventions":[{"name":"KHK7580","otherNames":["evocalcet"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Personally submitted written voluntary informed consent to participate in the study\n* Patients with a diagnosis of parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy.\n* Corrected serum calcium level is \\> 11.3 mg/dL at screening.\n\nExclusion Criteria:\n\n* Patients receiving cinacalcet hydrochloride within 2 weeks before screening\n* Patients diagnosed with hypercalcemia associated with malignant tumors other than parathyroid carcinoma.\n* Severe heart disease\n* Severe hepatic dysfunction\n* Uncontrolled hypertension and/or diabetes\n* Treatment with an investigational product (drug or medical device) in a clinical study or any study equivalent to clinical study within 12 weeks before screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number and Percentage of Patients Who Achived a Serum Corrected Ca Concentration of Under 10.3 mg/dL for at Least 2weeks During Titration Phase.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number and Percentage of Patients in Whom the Decrease in Serum Corrected Ca Concentration From the Baseline Was ≥ 1.0 mg/dL for ≥ 2 Weeks During the Titration Phase.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Corrected Ca Level","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.89","spread":"0.60"}]}]}]},{"type":"SECONDARY","title":"Serum Intact Parathyroid Hormone Level","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152.6","spread":"97.3"}]}]}]},{"type":"SECONDARY","title":"Serum Whole Parathyroid Hormone Level","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108.9","spread":"73.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":18},"commonTop":["Nasopharyngitis","Nausea","Chest pain","Cystitis","Influenza"]}}}